Abstract
A dual study was conducted to assess (1) the long-term antiparkinsonian action of amantadine without levodopa and (2) the advantage of combined amantadine and levodopa over single-drug therapy, including changes in symptom severity when placebo replaces amantadine but levodopa is maintained.
Good to excellent results were obtained in 25% of the total pool of 77 patients on amantadine. No decline in therapeutic effect took place during a mean follow-up of 21 months.
Thirty-seven patients with considerable residual deficit after single-drug therapy derived improvement from the second drug (levodopa or amantadine). Gains in neurological signs and activities of daily living (ADL) ranged between 50 and 60% and for timed skills close to 25%. Depending on the individual indices, between 64 and 100% of patients improved with the second drug.
Placebo instead of amantadine produced deterioration. There was 75% loss in ADL, 45% loss in timed skills and losses in neurological signs exceeded gains produced by two-drug therapy.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Appleton D. B., Eadie M. J., Sutherland J. M. The continued use of amantadine hydrochloride in parkinsonism. Med J Aust. 1971 Oct 2;2(14):707–709. doi: 10.5694/j.1326-5377.1971.tb92500.x. [DOI] [PubMed] [Google Scholar]
- Barbeau A., Mars H., Botez M. I., Joubert M. Amantadine-HCl (Symmetrel) in the management of Parkinson's disease: a double-blind cross-over study. Can Med Assoc J. 1971 Jul 10;105(1):42–passim. [PMC free article] [PubMed] [Google Scholar]
- Grelak R. P., Clark R., Stump J. M., Vernier V. G. Amantadine-dopamine interaction: possible mode of action in Parkinsonism. Science. 1970 Jul 10;169(3941):203–204. doi: 10.1126/science.169.3941.203. [DOI] [PubMed] [Google Scholar]
- Hunter K. R., Stern G. M., Laurence D. R., Armitage P. Amantadine in parkinsonism. Lancet. 1970 May 30;1(7657):1127–1129. doi: 10.1016/s0140-6736(70)91210-9. [DOI] [PubMed] [Google Scholar]
- Kastin A. J., Barbeau A. Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease. Can Med Assoc J. 1972 Dec 9;107(11):1079–1081. [PMC free article] [PubMed] [Google Scholar]
- Mann D. C., Pearce L. A., Waterbury L. D. Amantadine for Parkinson's disease. Neurology. 1971 Sep;21(9):958–962. doi: 10.1212/wnl.21.9.958. [DOI] [PubMed] [Google Scholar]
- Parkes J. D., Calver D. M., Zilkha K. J., Knill-Jones R. P. Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet. 1970 Feb 7;1(7641):259–262. doi: 10.1016/s0140-6736(70)90634-3. [DOI] [PubMed] [Google Scholar]
- Schwab R. S., England A. C., Jr, Poskanzer D. C., Young R. R. Amantadine in the treatment of Parkinson's disease. JAMA. 1969 May 19;208(7):1168–1170. [PubMed] [Google Scholar]
- Walker J. E., Potvin A., Tourtellotte W., Albers J., Repa B., Henderson W., Snyder D. Amantadine and levodopa in the treatment of Parkinson's disease. Clin Pharmacol Ther. 1972 Jan-Feb;13(1):28–36. doi: 10.1002/cpt197213128. [DOI] [PubMed] [Google Scholar]